EUVIMEDEUVIMED entdecken
Crossref

Discovery of Imidazo[1,2- b ]pyridazine Derivatives as Potent PI3K/mTOR Dual Inhibitors for the Treatment of Pulmonary Fibrosis

Wanjing Zeng, Xiaoyuan Hua, Zhengyang Wang, Kaiyin Li, Ying Yin, Xu-Wen Li iD, Suzhen Dong iD, Mingliang Ma iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c02587 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Wanjing Zeng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China No…. Hauptthemen laut MEDLINE: Pyridazines, Phosphoinositide-3 Kinase Inhibitors, TOR Serine-Threonine Kinases, Pulmonary Fibrosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, Shandong Laboratory Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The PI3K/AKT/mTOR pathway drives fibrotic progression in idiopathic pulmonary fibrosis (IPF). Our design strategy yielded a series of novel imidazo[1,2-b]pyridazine-based dual PI3K/mTOR inhibitors. Guided by molecular docking, structural optimization introduced phenolic hydroxyl and carboxylic acid groups, enhancing binding and antifibrotic abilities. Compound 11 exhibited potent inhibition (94.9% PI3Kα, 42.99% mTOR at 1 nM) and nanomolar antiproliferative effects in pulmonary fibroblasts (IC50 = 0.380 and 0.090 μM). In a bleomycin-induced pulmonary fibrosis model, compound 11 (15 mg/kg) reduced Ashcroft scores, hydroxyproline content, and collagen deposition while restoring lung architecture. Western blot analysis confirmed the downregulation of fibrosis-related proteins. Treated mice showed steady weight recovery. Besides, toxicity test results showed no distinct liver and kidney toxicity in 11-treated mice at therapeutic doses. This work identifies a promising IPF therapeutic lead and establishes a framework for optimizing imidazo[1,2-b]pyridazine scaffolds in antifibrotic drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridazinesPhosphoinositide-3 Kinase InhibitorsTOR Serine-Threonine KinasesPulmonary FibrosisImidazolesProtein Kinase InhibitorsMTOR InhibitorsAnimalsHumansMiceMolecular Docking SimulationStructure-Activity RelationshipPhosphatidylinositol 3-KinasesCell ProliferationMaleBleomycinDrug DiscoveryFibroblastsMice, Inbred C57BL

Substanzen

PyridazinesPhosphoinositide-3 Kinase InhibitorsTOR Serine-Threonine KinasesImidazolesPhosphatidylinositol 3-KinasesBleomycinProtein Kinase InhibitorsMTOR Inhibitors

Autor:innen und Institutionen

  • Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.
  • State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Key Laboratory of Brain Functional Genomics-Ministry of Education, School of Life Science, East China Normal University, Shanghai 200062, China.

ORCID-Profile: Xu-Wen Li, Suzhen Dong, Mingliang Ma

Förderung

  • Fundamental Research Funds for the Central Universities
  • Shandong Laboratory Program

Zitieren

APA

Zeng, W., Hua, X., Wang, Z., Li, K., Yin, Y., Li, X. W., Dong, S., & Ma, M. (2025). Discovery of Imidazo[1,2- b ]pyridazine Derivatives as Potent PI3K/mTOR Dual Inhibitors for the Treatment of Pulmonary Fibrosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02587

Vancouver

Zeng W, Hua X, Wang Z, Li K, Yin Y, Li XW, et al. Discovery of Imidazo[1,2- b ]pyridazine Derivatives as Potent PI3K/mTOR Dual Inhibitors for the Treatment of Pulmonary Fibrosis. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02587

BibTeX
@article{Zeng2025,
  author = {Zeng, Wanjing and Hua, Xiaoyuan and Wang, Zhengyang and Li, Kaiyin and Yin, Ying and Li, Xu-Wen and Dong, Suzhen and Ma, Mingliang},
  title = {Discovery of Imidazo[1,2- b ]pyridazine Derivatives as Potent PI3K/mTOR Dual Inhibitors for the Treatment of Pulmonary Fibrosis},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c02587}
}
Kostenlos starten →